Belzutifan-induced tumor regression in sporadic hemangioblastoma: a case report and literature review - Top-Institutions - MDSpire

Belzutifan-induced tumor regression in sporadic hemangioblastoma: a case report and literature review

  • By

  • Rebekka E. Hooks

  • Niket Yadav

  • Mark Willy L. Mondia

  • Georgios Mantziaris

  • Alaa Saleh

  • Anna Vi Jones

  • Matthew McCord

  • Melike Mut

  • Ashok R. Asthagiri

  • Benjamin W. Purow

  • February 14, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute (NCI), National Institutes of Health
    National Cancer Institute (NCI), National Institutes of Health

    Bethesda, MD

    Key Differentiators

    • Neuro-oncology
    • Molecular Oncology
    • Genetics

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Targeted Cancer Therapy
    • Genomic Medicine

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Genetic Tumor Syndromes

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Genetic Disorders

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neurosurgery
    • Neurogenetics
    • Oncology

Original Source(s)

Belzutifan-induced tumor regression in sporadic hemangioblastoma: a case report and literature review

  • by Rebekka E. Hooks, Niket Yadav, Mark Willy L. Mondia, Georgios Mantziaris, Alaa Saleh, Anna Vi Jones, Matthew McCord, Melike Mut, Ashok R. Asthagiri, Benjamin W. Purow

  • February 14, 2026

Related Content

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer